|
|
 |
|
Viewing report
|
|
|
|
Hypercholesterolemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, April 2011, Pages: 72
Hypercholesterolemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hypercholesterolemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hypercholesterolemia market. The report identifies the key trends shaping and driving the global hypercholesterolemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hypercholesterolemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global hypercholesterolemia therapeutics market is predicted to witness marginal growth by 2017. This is primarily due to the probable launch of two novel therapies, MK-0524A and MK-0524B, from Merck & Co., Inc. The approval of Livalo (pitavastatin) in Europe will also positively impact the global hypercholesterolemia therapeutics market. However, many drugs are expected to lose their patent in the coming years like Lipitor (atorvastatin) and Lescol (fluvastatin) losing patent by 2011, followed by Niaspan (Niacin) in 2013, Pravachol (pravastatin) in 2014 and Crestor (rosuvastatin) in 2016. GlobalData’s analysis suggests that the global hypercholesterolemia therapeutics market was worth $29 billion in 2010. The market is forecast to show a rise at a compound annual growth rate (CAGR) of 4%.
Scope
The report provides information on the key drivers and challenges of the hypercholesterolemia market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) hypercholesterolemia market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Apolipoprotein-B synthes inhibitors, beta-selective thyroid hormone receptor agonists, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, HMG-CoA reductase inhibitors, MTP-I inhibitors, PCSK9 inhibitors, prostaglandin D2 Receptor 1 (DP1) antagonists, and combination therapies.
- Analysis of the current and future competition in the seven key countries hypercholesterolemia market. Key market players covered are Abbott, Aegerion Pharmaceuticals, AstraZeneca, Bristol- Myers Squibb, Merck and Sanofi-aventis.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hypercholesterolemia therapeutics market.
- Analysis of key recent licensing and partnership agreements in hypercholesterolemia market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hypercholesterolemia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hypercholesterolemia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hypercholesterolemia market landscape? – Identify, understand and capitalize.
|
|
|
|
